PEPG — PepGen Inc.

PepGen (PEPG) Q4 2023 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2023, PepGen had $110.4 million in cash and cash equivalents, down from $181.8 million in 2022. Following a stock offering on February 9, 2024, which raised approximately $80 million, the cash runway is extended into 2026.
• Net Loss: The net loss for Q4 2023 was $19.5 million, with a total net loss of $78.6 million for the full year.
• R&D Expenses: R&D expenses for Q4 were $16.3 million, totaling $68.1 million for the year, reflecting increased costs associated with clinical trials.
• G&A Expenses: General and administrative expenses were $4.5 million for Q4 and $16.6 million for the full year, primarily due to increased personnel costs.

2. Strategic Updates and Business Highlights

• Clinical Trials: PepGen initiated its first inpatient clinical trials for its EDO platform targeting Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
  • DMD Program (PGN-EDO51): Completed enrollment for the 5 mg/kg cohort in the Phase II CONNECT1 trial. Plans to escalate to a 10 mg/kg cohort pending safety data review. Preliminary data expected mid-2024.
  • DM1 Program (PGN-EDODM1): The clinical hold was lifted, and the first patient was dosed in the Phase I FREEDOM-DM1 trial. Fast track designation received from the FDA. Preliminary data expected in the second half of 2024.
• Research Initiatives: Continued advancement of preclinical candidates, including PGN-EDO53 targeting exon 53 of the dystrophin transcript.

3. Forward Guidance and Outlook

• PepGen anticipates multiple clinical data readouts in 2024, including preliminary data from the CONNECT1 trial and the FREEDOM-DM1 trial.
• The company remains committed to advancing its clinical programs with a focus on achieving disease-modifying outcomes for patients.

4. Challenges and Points of Concern

• Financial Position: The significant decrease in cash reserves from the previous year raises concerns about long-term sustainability without continued funding.
• Clinical Risks: The success of ongoing trials is critical; any adverse safety data could impact the progression to higher dose cohorts or future trials.
• Competitive Landscape: The company faces competition in the exon-skipping therapy space, particularly from other companies with similar programs, which may affect market positioning.

5. Notable Q&A Insights

• Dystrophin Production: Management clarified that they expect to see greater than 1% dystrophin production over background levels in the 5 mg/kg cohort, with potential for over 9% at the 10 mg/kg dose, which would be a significant achievement in the field.
• Mechanism of Action: The EDO platform is designed to specifically target pathogenic RNA without degrading non-pathogenic RNA, which could lead to improved safety profiles and efficacy.
• Regulatory Discussions: Ongoing discussions with regulators regarding primary endpoints for DM1 therapies, with expectations that splicing correction will correlate with functional outcomes in patients.

Overall, PepGen is positioned for potential breakthroughs in the treatment of DMD and DM1, but faces financial and clinical risks that could impact its strategic objectives.